Insights
Search Results
Client Highlights
12.12.25
Wilson Sonsini Advises Denali Therapeutics on $200 Million Public Offering
On December 10, 2025, Denali Therapeutics, a biopharmaceutical company focused on therapies for neurodegenerative and lysosomal storage diseases, announced the pricing of its underwritten public offering of 9,142,857 shares of its common stock at a price to the public of $17.50 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 2,285,714 shares of common stock at a price of $17.49 per pre-funded warrant, which represents the per share public offering price of each share of common stock less the $0.01 per share exercise price for each pre-funded warrant. All of the shares and pre-funded warrants are to be sold by Denali Therapeutics. Denali Therapeutics expects to receive total gross proceeds of approximately $200 million before deducting underwriting discounts and commissions and other offering expenses and excluding any exercise of the underwriters’ option to purchase additional shares. Wilson Sonsini Goodrich & Rosati advised Denali Therapeutics on the transaction.
Client Highlights
12.08.25
Firm Advises Check Point on $2 Billion Convertible Senior Notes Offering
On December 8, 2025, Check Point Software Technologies Ltd. completed an upsized offering of $2 billion aggregate principal amount of convertible senior notes due 2030 in a private transaction. The offering amount included the exercise in full of the option that Check Point had granted to the initial purchasers to purchase up to an additional $250 million of notes. In connection with the offering, Check Point entered into privately negotiated capped call transactions with an affiliate of one of the initial purchasers and certain other financial institutions.
Client Highlights
2.28.24
Wilson Sonsini Advises Denali Therapeutics on $500 Million Private Placement Financing
On February 27, 2024, California-based Denali Therapeutics, a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases, announced that it has entered into a securities purchase agreement with certain existing accredited investors to issue and sell an aggregate of 3,244,689 shares of its common stock at a price of $17.07 per share and pre-funded warrants to purchase 26,046,065 shares of common stock at a purchase price of $17.06 per pre-funded warrant share, through a private investment in public equity (PIPE) financing. Denali Therapeutics anticipates gross proceeds from the PIPE to be approximately $500 million. Wilson Sonsini Goodrich & Rosati advised Denali Therapeutics on the transaction.
Client Highlights
10.25.22
Wilson Sonsini Advises Denali Therapeutics on $316 Million Public Offering
On October 24, 2022, Denali Therapeutics, a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, announced the close of its upsized underwritten public offering of 11,933,962 shares of its common stock at a price to the public of $26.50 per share, which includes the exercise in full by the underwriters of their option to purchase additional shares. The total gross proceeds from the offering, before deducting underwriters’ discounts and commissions and estimated offering expenses, are approximately $316 million. All of the shares in the offering were offered by Denali Therapeutics.
Client Highlights
6.11.21
Wilson Sonsini Advises Underwriters on $1.2 Billion Marqeta IPO
On June 8, 2021, Marqeta announced the pricing of its initial public offering of 45,454,546 shares of its Class A common stock at a public offering price of $27 per share, with gross proceeds to the company of over $1.2 billion. Marqeta also granted the underwriters a 30-day option to purchase up to an additional 6,818,181 shares of its Class A common stock at the initial public offering price, less underwriting discounts and commissions. The company's stock began trading on the Nasdaq Global Select Market under the ticker symbol "MQ" on June 9. The offering closed on June 11.
Client Highlights
3.26.21
Wilson Sonsini Advises Underwriters on thredUP IPO
On March 25, 2021, ThredUp Inc. (thredUP) announced the pricing of its initial public offering of 12,000,000 shares of its Class A common stock at a price to the public of $14 per share. The shares began trading on the Nasdaq Global Select Market on March 26, 2021, under the symbol "TDUP," and the offering is expected to close on March 30, 2021, subject to customary closing conditions. In addition, thredUP has granted the underwriters a 30-day option to purchase up to an additional 1,800,000 shares of Class A common stock at the initial public offering price, less underwriting discounts and commissions.
Client Highlights
12.07.17
Denali Therapeutics Announces Initial Public Offering
On December 7, 2017, Denali Therapeutics, a biotech company that develops new molecular therapies for neurodegenerative diseases, announced its initial public offering of 13,888,888 million shares of its Class A common stock at a price to the public of $18 per share, resulting in estimated net proceeds to the company of $250,000,000. The shares began trading on the Nasdaq exchange on December 8, 2017, under the ticker symbol "DNLI." Wilson Sonsini Goodrich & Rosati represented Denali in the offering.